GlassScriptPhysician profile
Roxy L Shortridge
NPI 1497587042
$2,244.42
in general payments reported to CMS, 2019-2025
36 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $157 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $321.74 | 2024-2025 | |
| Daiichi Sankyo INC. | $153.43 | 2024-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $122.93 | 2025 | Tecvayli, Rybrevant, Darzalex |
| Incyte Corporation | $119.04 | 2025 | Jakafi, Monjuvi, Zynyz |
| Intera Oncology, INC | $112.29 | 2025 | Intera |
| Regeneron Healthcare Solutions, INC. | $111.28 | 2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $105.39 | 2025 | Ninlaro |
| Pharmacosmos Therapeutics INC. | $92.24 | 2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $82.63 | 2025 | |
| Celgene Corporation | $81.01 | 2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $80.58 | 2024-2025 | |
| Astellas Pharma US INC | $70.47 | 2025 | Padcev, Vyloy, Xtandi |
| Puma Biotechnology, INC. | $69.24 | 2024-2025 | |
| Glaxosmithkline, LLC. | $61.45 | 2025 | Ojjaara |
| Lilly USA, LLC | $55.13 | 2025 | Verzenio, Jaypirca, Retevmo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.63 | 2025 | Keytruda, Lynparza |
| Genmab U.S., INC. | $51.76 | 2024-2025 | Epkinly |
| Pfizer INC. | $49.13 | 2025 | |
| Tersera Therapeutics LLC | $47.79 | 2024-2025 | Xermelo |
| Eisai INC. | $44.80 | 2025 | |
| Emd Serono, INC. | $40.22 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.37 | 2025 | Opdivo |
| Deciphera Pharmaceuticals INC. | $31.73 | 2025 | Qinlock, Romvimza |
| Spectrum Pharmaceuticals INC. | $25.97 | 2025 | Rolvedon |
| Genzyme Corporation | $25.24 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.06 | 2025 | Calquence |
| Karyopharm Therapeutics INC. | $21.92 | 2025 | Xpovio |
| Taiho Oncology, INC. | $20.84 | 2025 | |
| Sobi, INC | $19.38 | 2025 | |
| Geron Corporation | $19.32 | 2025 | Rytelo |
| Gilead Sciences, INC. | $18.64 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.37 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Array Biopharma INC | $15.96 | 2025 | Braftovi, Lorbrena, Xtandi |
| Exelixis INC. | $15.69 | 2024 | Cabometyx |
| Abbvie INC. | $15.22 | 2025 | |
| Genentech USA, INC. | $14.53 | 2024 | Columvi, Polivy, Lunsumio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxy Shortridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.